FOFumihiro Oshita

Fumihiro Oshita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fumihiro Oshita has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 July 2016
      • Vol. 11  (3) , 189-194

    Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.

    by Fumihiro Oshita, Rika Kasajima, Yohei Miyagi

    We evaluated multiple oncogenic mutations and fusion genes in small specimen obtained by bronchoscopy. Eight patients with lung cancer were recruited, 3 small cell lung cancer, 3 non-small cell lung cancer, 1 adenocarcinoma and 1 squamous cell carcinoma. A median value of extracted RNA and DNA amounts from specimen was 1573 ng (range 367.5 to 8900) and 6700 ng (range 550 to 68000 ng), respectively. We applied amplicon sequencing panels that cover exon regions of 41 genes related to lung tumorigenesis as well as total 61 major variants of ALK, ROS, RET or NTRK1 fusion transcripts. Nineteen of 41 gene mutations were detected in our isolated DNAs of 8 patients. We could detect four to eleven mutations in each specimen; however the mutation combination in each 8 patients were different. The most common genetic alterations were TP53, KMT2D, MET, NOTCH2 and SETD2, which were detected in 4 to 6 patients. We did not detect fusion transcripts of ALK, ROS, RET and NTRK1 in every specimen. In conclusion, multiplex genomic test was performed on small amounts specimen of bronchoscopy biopsy with a 100% success rate. Such testing is considered to be able to assist physicians in matching patients with approved or experimental targeted treatments.


  • Open Access

    Feasibility study of docetaxel plus bevacizumab as first line therapy for elderly patients with advanced non-small-cell lung cancer: Thoracic Oncology Research Group (TORG) 1014

    by Yusuke Takagi, Yukio Hosomi, Fumihiro Oshita, Hiroaki Okamoto, Nobuhiko Seki, Koichi Minato, Hiromi Aono, Kouzo Yamada, Yusuke Okuma, Naoya Hida, et al.

    Docetaxel monotherapy is one of the standard treatments for non-small-cell lung cancer in elderly patients. The addition of bevacizumab to docetaxel seems promising; however, the feasibility of this combination has not been investigated in such patients. Patients with advanced non-squamous non-small-cell lung cancer aged 70 years or older who had not previously received cytotoxic chemotherapy were enrolled. Patients in the Level 0 cohort received docetaxel 60 mg/m2 and bevacizumab 15 mg/kg, whereas those in the Level-1 cohort received docetaxel 50 mg/m2 and bevacizumab 15 mg/kg. Chemotherapy was repeated 3 weekly for six cycles. The primary endpoint was toxicity and the secondary endpoints were response rate, progression-free survival, overall survival, and proportion of patients who underwent three or more cycles of chemotherapy. Twenty-one patients were enrolled from December 2010 to September 2012 at six institutes. Of the nine patients enrolled in Level 0, two experienced dose-limiting toxicity (febrile neutropenia and prolonged Grade 4 neutropenia in one patient, and Grade 3 infection in another patient) during the first cycle. Enrollment to the Level 0 cohort was terminated because two patients developed Grade 4 sepsis during later cycles. The remaining 12 patients were enrolled in the Level-1 cohort, in which two dose-limiting toxicities (prolonged Grade 4 neutropenia and Grade 3 increased aminotransferase level) were observed. No patient in the Level-1 cohort experienced Grade 4 nonhematologic toxicity. Grade 4 neutropenia occurred in 89 % of Level 0 patients and 50 % of Level-1 patients. The proportion of patients who experienced Grade 3/4 infection, febrile neutropenia or sepsis was 44 % in the Level 0 cohort, and 8 % in the Level-1 cohort. The overall response rate to chemotherapy and progression-free survival were 29 % (95 % CI, 11–52 %) and 5.9 months (95 % CI, 3.6–9.1 months), respectively. Efficacy outcomes did not differ significantly between the cohorts. Toxicities were tolerable in level-1 cohort. The recommended dose of combination chemotherapy with docetaxel and bevacizumab for elderly patients was determined as 50 mg/m2 of docetaxel and 15 mg/kg of bevacizumab and toxicities were tolerable. Further studies are warranted. UMIN Clinical Trial Registry; UMIN000004240.


  • Phase II Study of Nedaplatin / Irinotecan for Advanced Squamous Cell Carcinoma of the Lung(Torg0910)

    by Shunichiro Iwasawa, Yuichi Takiguchi, Haruhiro Saito, Yamada Kouzo, Noriyuki Masuda, Hiroaki Okamoto, Yukio Hosomi, Kazuma Kishi, Fumihiro Oshita, Koshiro Watanabe

    Background: A synergistic interaction between nedaplatin (NP) and irinotecan (CPT) has been demonstrated in three-dimensional analytical models (Clin Cancer Res 2001). Phase I/II studies for lung cancer showed high efficacy of the combination of NP and CPT (Cancer Chemother Pharmacol 2003). In addition, a meta-analysis suggested that the combination of NP and CPT was more feasible in squamous cell carcinoma (SCC) than non-squamous cell carcinoma (J Thorac Oncol. 2011). This study explored the efficacy and safety of an NP and CPT regimen in SCC of the lung. Methods: We conducted a multicenter phase II study of NP and CPT for stage III and IV SCC of the lung. Treatment consisted of 4 to 6 cycles of NP at 100mg/m2 (day 1) and CPT at 60mg/m2 (days 1 and 8) every 4 to 5 weeks. The primary endpoint was the response rate and secondary endpoints were overall and progression-free survival rates, and safety. Results: Fifty patients were registered and evaluated. Twenty-seven patients received 4 to 6 cycles of chemotherapy. A median of 4 cycles were given. One patient achieved a complete response and sixteen showed partial responses, with an overall response rate of 34.0% (95% confidence interval 21.2% to 48.8%). The disease control rate was 74.0%. The median progression free survival time was 4.3 months. The major toxicities included grade 4 anemia (10.0%), neutropenia (46.0%) and thrombocytopenia (10.0%), and grade 3 or 4 anorexia, diarrhea, hyponatremia, febrile neutropenia and infection occurred in 22.0%, 12.0%, 12.0%, 16.0% and 10.0% of patients, respectively. All of the toxicities were manageable and no treatment-related deaths were observed. Conclusions: The NP and CPT combination therapy is feasible for patients with advanced SCC of the lung.

  • Open Access

    Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer

    by Teppei Nishii, Tomoyuki Yokose, Yohei Miyagi, Yataro Daigo, Hiroyuki Ito, Tetsuya Isaka, Kentaro Imai, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, et al.

    The rapid aging of the population in Japan has been accompanied by an increased rate of surgery for lung cancer among elderly patients. It is thus an urgent priority to map out a treatment strategy for elderly patients with primary lung cancer. Although surgical resection remains standard treatment for early stage non–small-cell lung cancer (NSCLC), it is now essential to confirm the status of epidermal growth factor receptor (EGFR) gene mutations when planning treatment strategies. Furthermore, several studies have reported that EGFR mutations are an independent prognostic marker in NSCLC. However, the relations between age group and the molecular and pathological characteristics of NSCLC remain unclear. We studied the status of EGFR mutations in elderly patients with NSCLC and examined the relations of EGFR mutations to clinicopathological factors and outcomes according to age group. A total of 388 consecutive patients with NSCLC who underwent complete tumor resection in our hospital from 2006 through 2008 were studied retrospectively. Formalin-fixed, paraffin-embedded tissue sections were used to isolate DNA from carcinoma lesions. Mutational analyses of EGFR gene exons 19, 20, and 21 and KRAS gene exons 12 and 13 were performed by loop-hybrid mobility shift assay, a highly sensitive polymerase chain reaction-based method. EGFR mutations were detected in 185 (47.7%) and KRAS mutations were detected in 33 (8.5%) of the 388 patients. EGFR mutations were found in a significantly higher proportion of patients younger than 80 years (younger group; 178/359, 49.6%) than in patients 80 years or older (older group; 7/29, 24.1%) (P = 0.008). In contrast, KRAS mutations were more common in the older group (6/29, 20.7%) than in the younger group (27/359, 7.5%) (P = 0.014). The older group showed a trend toward a higher rate of 5-year overall survival among elderly patients with EGFR mutations (100%) than among those with wild-type EGFR (66.2%), but the difference was not significant. Our results suggest that the EGFR status of patients with NSCLC differs between patients 80 years or older and those younger than 80 years. EGFR mutation status might be a prognostic marker in elderly patients with completely resected NSCLC.


    • 1 January 2013
      • Vol. 10  (3) , 203-8

    Prospective study of paclitaxel and irinotecan for elderly patients with unresectable non-small cell lung cancer.

    by Fumihiro Oshita, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Kouzo Yamada

    We conducted a phase II study of combination chemotherapy with paclitaxel (Pac) and irinotecan (CPT) to determine the effects and toxicities in patients 70 years or older with unresectable non-small cell lung cancer (NSCLC). Eligible patients were entered to receive three courses of Pac at 160 mg/m2 and CPT at 60 mg/m2 every 2-3 weeks. Twenty-one patients were registered. Thirteen patients were male and 8 were female, with a median age of 72 years (range: 70-82 years). Eight patients had a performance status (PS) of 0 and the other 13 patients had a PS of 1. Six and 15 patients were stage IIIB and stage IV, respectively. Ten patients received 3 to 6 cycles of the chemotherapy. Of the hematological toxicities, grade 4 neutropenia was observed in 23.8% of the patients. Of the non-hematological toxicities, grade 3 or 4 fatigue, anorexia and nausea were observed in 5, 3 and 4 patients, respectively. Three of 6 patients with infection developed grade 3 pneumonia. Grade 3 allergy with rash occurred in a patient. Cerebral infarction occurred in two patients and grade 3 peripheral neuropathy in one. The outcome of the Pac and CPT regimen in 21 patients was 8 PR, 10 SD and three PD, and the response rate was 38.1% The median survival time was 9.1 months. The one- and 2-year survival rates were 38.1% and 19.0%, respectively. The Pac plus CPT regimen is feasible and active with moderate toxicity for elderly patients with NSCLC.

  • Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancer

    by Fumihiro Oshita, Makiko Sugiura, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Kouzo Yamada


  • Open Access

    The place of TKI in the treatment of EGFR mutation-positive lung cancer

    by Fumihiro Oshita, Shuji Murakami

    The place of TKI in the treatment of EGFR mutation-positive lung cancer

    • 1 April 2012
      • Vol. 32  (4) , 1453-6

    Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung.

    by Yoshiyuki Kenmotsu, Fumihiro Oshita, Makiko Sugiura, Shuji Murakami, Tetsuro Kondo, Haruhiro Saito, Kouzo Yamada

    No standard chemotherapy has been established for patients with large-cell neuroendocrine carcinoma (LCNEC). Patients with LCNEC of the lung were treated with nedaplatin (NP) at 50 mg/m(2) and irinotecan at 50 mg/m(2) on days 1 and 8 every four weeks for four cycles. Data for 18 of the LCNEC patients were retrospectively analyzed. All patients were male, with a performance status 0 or 1, and the median age was 68 (range 58-80) years. Nine patients received adjuvant chemotherapy after undergoing complete surgical resection. Fourteen patients were able to receive four cycles of nedaplatin and irinotecan. Grade 4 leukopenia and neutropenia occurred in 5.6% and 16.7%, respectively. Four patients experienced grade 3 non-hematologic toxicities, such as diarrhea, enterocolitis, duodenal perforation and myocardial infarction. There were no treatment-related deaths. Two patients achieved complete response and four achieved partial response, and the median survival time was 12.3 months for the nine patients with advanced disease. Nedaplatin plus irinotecan is effective and safe for patients with LCNEC of the lung.


  • Growth rate of lung cancer recognized as small solid nodule on initial CT findings

    by Kei Mikita, Haruhiro Saito, Yuji Sakuma, Tetsuro Kondo, Takeshi Honda, Syuji Murakami, Fumihiro Oshita, Hiroyuki Ito, Masahiro Tsuboi, Haruhiko Nakayama, et al.